# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA has approved Eli Lilly's Ebglyss for moderate-to-severe eczema in patients 12 and older. The treatment is administe...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $885 price target.
Correction: JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1...
JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $1050 to $1...
Citigroup analyst Peter Verdult reinstates Eli Lilly (NYSE:LLY) with a Buy and announces $1060 price target.